Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Lenihan

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Heart (British Cardiac Society)|January 24, 2024
Moving towards establishing centres of excellence in cardiac amyloidosis: an International Cardio-Oncology Society statementRichard Cheng, Michelle M Kittleson, Ashutosh D Wechalekar, et al.
Cancer Medicine|March 27, 2026
Standardizing the Clinical Approach to Cancer Therapy-Related Cardiac Dysfunction: Applying Cardio-Oncology Guidelines as a Practical Tool for Hematology and Oncology ProvidersAbdelrahman Ali, Suparna C Clasen, Anne Blaes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2019
Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple MyelomaRobert F Cornell, Bonnie Ky, Brendan M Weiss, et al.
European Heart Journal|December 14, 2021
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statementJoerg Herrmann, Daniel Lenihan, Saro Armenian, et al.
JAMA Oncology|November 13, 2025
Immune Checkpoint Inhibitor-Associated Cardiovascular Toxic Effects: International Cardio-Oncology Society Position StatementJoerg Herrmann, Ana Barac, Joseph Carver, et al.
European Journal of Heart Failure|August 28, 2024
The right heart in patients with cancer. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-OncologyKalliopi Keramida, Dimitrios Farmakis, Amina Rakisheva, et al.
European Heart Journal|August 26, 2022
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)Alexander R Lyon, Teresa López-Fernández, Liam S Couch, et al.
European Heart Journal. Cardiovascular Imaging|August 26, 2022
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)Alexander R Lyon, Teresa López-Fernández, Liam S Couch, et al.
European Journal of Heart Failure|August 1, 2024
Cardiovascular toxicities of immune therapies for cancer - a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-OncologyCarlo Gabriele Tocchetti, Dimitrios Farmakis, Yvonne Koop, et al.
European Journal of Heart Failure|May 29, 2020
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology SocietyAlexander R Lyon, Susan Dent, Susannah Stanway, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Heart (British Cardiac Society)|January 24, 2024
Moving towards establishing centres of excellence in cardiac amyloidosis: an International Cardio-Oncology Society statementRichard Cheng, Michelle M Kittleson, Ashutosh D Wechalekar, et al.
Cancer Medicine|March 27, 2026
Standardizing the Clinical Approach to Cancer Therapy-Related Cardiac Dysfunction: Applying Cardio-Oncology Guidelines as a Practical Tool for Hematology and Oncology ProvidersAbdelrahman Ali, Suparna C Clasen, Anne Blaes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2019
Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple MyelomaRobert F Cornell, Bonnie Ky, Brendan M Weiss, et al.
European Heart Journal|December 14, 2021
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statementJoerg Herrmann, Daniel Lenihan, Saro Armenian, et al.
JAMA Oncology|November 13, 2025
Immune Checkpoint Inhibitor-Associated Cardiovascular Toxic Effects: International Cardio-Oncology Society Position StatementJoerg Herrmann, Ana Barac, Joseph Carver, et al.
European Journal of Heart Failure|August 28, 2024
The right heart in patients with cancer. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-OncologyKalliopi Keramida, Dimitrios Farmakis, Amina Rakisheva, et al.
European Heart Journal|August 26, 2022
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)Alexander R Lyon, Teresa López-Fernández, Liam S Couch, et al.
European Heart Journal. Cardiovascular Imaging|August 26, 2022
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)Alexander R Lyon, Teresa López-Fernández, Liam S Couch, et al.
European Journal of Heart Failure|August 1, 2024
Cardiovascular toxicities of immune therapies for cancer - a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-OncologyCarlo Gabriele Tocchetti, Dimitrios Farmakis, Yvonne Koop, et al.
European Journal of Heart Failure|May 29, 2020
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology SocietyAlexander R Lyon, Susan Dent, Susannah Stanway, et al.
Pageof 8